Products

Sugistran 12.5 mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Oncology. Sugistran 12.5 mg Capsule is a high-potency, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sugistran is a cornerstone in modern precision oncology. Manufactured by Zuventus Healthcare, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 12.5 mg strength allows for precise dose titration, ensuring that patients receive the optimal therapeutic benefit while managing systemic tolerability. Therapeutic Indications and Global Clinical Usage Sugistran 12.5 mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sugistran 12.5mg Works Sugistran employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sugistran helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sugistran 12.5 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Flexibility: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration) or hair depigmentation during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sunisam 12.5mg Capsule (Sunitinib): Targeted Therapy for Advanced Renal and Gastrointestinal Malignancies Sunisam 12.5 mg Capsule is a high-efficacy, oral antineoplastic medication containing Sunitinib as its active pharmaceutical ingredient. Manufactured by Samarth Life Sciences, Sunisam belongs to the class of drugs known as Tyrosine Kinase Inhibitors (TKIs). It is a multi-targeted therapy designed to inhibit the growth and spread of cancer cells by blocking specific enzymes that promote tumor proliferation and angiogenesis. The 12.5mg strength provides clinicians with the flexibility needed for precise dose adjustments based on individual patient tolerance and clinical response. Therapeutic Indications and Clinical Usage Sunisam 12.5mg is globally utilized in oncology for the treatment of several aggressive conditions: Advanced Renal Cell Carcinoma (RCC): Indicated as a primary treatment for metastatic kidney cancer to slow disease progression and improve survival outcomes. Gastrointestinal Stromal Tumors (GIST): Prescribed for patients whose disease has progressed or who are unable to tolerate imatinib mesylate therapy. Pancreatic Neuroendocrine Tumors (pNET): Used for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment for RCC: Used in specific clinical settings to reduce the risk of cancer recurrence in patients who have undergone a nephrectomy. Mechanism of Action: How Sunisam 12.5mg Works Sunisam disrupts the “fueling“ mechanisms of a tumor through a multi-targeted approach: Anti-Angiogenesis: It targets Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). By blocking these signals, Sunisam prevents the tumor from developing the new blood vessels it needs for oxygen and nutrient supply. Inhibition of Proliferation: It targets other receptor tyrosine kinases (such as KIT and FLT3) that are responsible for the rapid and uncontrolled division of malignant cells. Metastasis Suppression: By interfering with these critical signaling pathways, the medication helps limit the cancer's ability to migrate and invade other parts of the body. Dosage and Administration Guidelines Method of Administration: Sunisam 12.5 mg should be taken orally. Capsules must be swallowed whole with water; do not open, crush, or chew them. Food Interaction: It can be taken with or without food, but taking it at a consistent time each day is recommended. Standard Regimen (RCC/GIST): Often follows a “4 weeks on, 2 weeks off“ schedule (the 4/2 cycle). Continuous Regimen (pNET): Generally administered as a continuous daily dose without a rest period. Clinical Monitoring: Dosage may be modified by a healthcare professional based on blood counts, blood pressure, and thyroid function tests. Safety Profile and Precautions Patients using Sunisam 12.5 mg should be under the regular supervision of an oncologist to monitor for: Cardiovascular Health: Monitoring for hypertension and changes in heart function (LVEF). Thyroid Function: Regular checks for hypothyroidism, a common side effect of TKI therapy. Hematological Stability: Periodic blood tests to check for neutropenia or thrombocytopenia. Dermatological Effects: Potential skin discoloration (yellowing), hair color changes, or hand-foot syndrome (blistering/redness on palms and soles). Wound Healing: Sunitinib may affect the body’s ability to heal wounds; treatment is usually paused before and after surgical procedures. Storage and Handling Temperature: Store at room temperature between 20°C and 25°C. Packaging: Keep capsules in their original container to protect them from light and moisture. Safety: Ensure the medication is kept out of reach of children and handled only by the prescribed patient or trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sunixar 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Malignancies Sunixar 12.5 mg Capsule is a high-efficacy oral antineoplastic agent containing the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sunixar is a cornerstone in modern precision oncology. Manufactured by Beacon Pharmaceuticals, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 12.5 mg strength allows for precise dose titration, ensuring that patients receive the optimal therapeutic benefit while managing systemic tolerability. Therapeutic Indications and Global Clinical Usage Sunixar 12.5 mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sunixar 12.5mg Works Sunixar employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sunixar helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sunixar 12.5 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Flexibility: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with Sunixar 12.5 mg requires consistent medical oversight to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration) or hair depigmentation during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutekast 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Inhibition for Advanced Oncology Sutekast 12.5 mg Capsule is a potent, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. It is a specialized multi-targeted receptor tyrosine kinase (RTK) inhibitor designed to disrupt the life cycle of cancer cells. Manufactured by Aprazer Healthcare, Sutekast 12.5 mg is a vital therapeutic intervention in modern precision medicine, specifically engineered to inhibit tumor growth and prevent the formation of blood vessels that nourish malignant cells. Therapeutic Indications and Clinical Usage Sutekast 12.5 mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated as a primary treatment for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Treatment: Utilized in certain high-risk scenarios to prevent cancer recurrence following a nephrectomy. Mechanism of Action: How Sutekast 12.5mg Works Sutekast works through a dual-action approach—inhibiting both tumor cell signaling and the tumor's blood supply: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutekast helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutekast 12.5 mg is an oral medication. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Flexibility: It can be taken with or without food but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with Sutekast 12.5mg requires consistent medical oversight to manage potential side effects: Cardiovascular Health: Regular blood pressure monitoring is essential, as Sunitinib can cause hypertension. Hematological Checks: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair: Patients may experience skin yellowing (discoloration) or hair depigmentation during the treatment cycle. Organ Function: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lynide 5mg Capsule (Lenalidomide): Precision Immunomodulatory Therapy for Oncology Care Lynide 5mg Capsule is a high-efficacy oral antineoplastic and immunomodulatory medication containing the active pharmaceutical ingredient Lenalidomide. Manufactured by Glenmark Pharmaceuticals, a globally recognized leader in high-quality medicine, Lynide belongs to the class of drugs known as Immunomodulatory Imide Drugs (IMiDs). The 5mg strength is a vital dosage form used extensively for maintenance therapy, precise dose titration, and the management of chronic hematological malignancies. Therapeutic Indications and Clinical Usage Lynide 5mg is integrated into international oncology protocols for the management of several complex conditions: Multiple Myeloma (MM) Maintenance: Used as a long-term strategy following an autologous stem cell transplant (ASCT) to prolong progression-free survival and prevent disease relapse. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Administered in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lynide 5mg Works Lynide exerts a multi-pathway biological effect to combat malignant cells while enhancing the body's natural defenses: Cereblon Binding: It binds to the protein Cereblon, part of the E3 ubiquitin ligase complex. This leads to the targeted degradation of essential transcription factors that malignant cells rely on for survival. Immune System Activation: It stimulates the proliferation and activity of T-cells and Natural Killer (NK) cells, significantly increasing the body's innate ability to identify and eliminate tumor cells. Anti-Angiogenesis: It inhibits the development of new blood vessels (angiogenesis) that tumors require for oxygen and nutrient supply. Cytokine Regulation: It suppresses the production of pro-inflammatory cytokines such as TNF-α and IL-6, which are known to promote the growth of myeloma cells in the bone marrow microenvironment. Dosage and Administration Guidelines Administration: Lynide 5 mg is an oral medication. Capsules must be swallowed whole with water. Do not open, crush, or chew the capsules. Consistency: It should be taken at approximately the same time each day, with or without food. Cycle-Based Therapy: In many maintenance protocols, it is taken daily on a 21-day or 28-day cycle. Always adhere to the specific regimen prescribed by your hematologist-oncologist. Dose Flexibility: The 5 mg strength allows clinicians to precisely adjust the dose to manage hematological toxicities or accommodate renal impairment. Safety Profile and Clinical Monitoring Due to its potent biological activity, Lynide 5 mg requires vigilant medical oversight: Hematological Monitoring: Regular Complete Blood Counts (CBC) are mandatory to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Risk: Lenalidomide increases the risk of blood clots. Prophylactic anticoagulation (e.g., Aspirin) is frequently prescribed concurrently. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients, regardless of gender or age. Common Side Effects: These may include fatigue, diarrhea, muscle cramps, skin rashes, and nausea. Storage and Global Handling Instructions Temperature: Store at room temperature (20°C to 25°C). Original Packaging: Keep capsules in the original blister pack to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the medication; if a capsule is broken, wash the area immediately with soap and water. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenome 5mg Capsule (Lenalidomide): Advanced Immunomodulatory Therapy for Hematological Oncology Lenome 5mg Capsule is a potent, oral antineoplastic and immunomodulatory medication containing the active pharmaceutical ingredient Lenalidomide. Manufactured by Intas Pharmaceuticals Ltd., a global leader in high-quality oncology generics, Lenome belongs to the class of medications known as Immunomodulatory Imide Drugs (IMiDs). The 5mg strength is a vital dosage form used extensively for maintenance therapy, dose titration, and the management of chronic blood-related malignancies. Therapeutic Indications and Clinical Usage Lenome 5mg is integrated into international oncology protocols for the following conditions: Multiple Myeloma (MM): Used as a maintenance treatment in adult patients following an autologous stem cell transplant (ASCT) or in combination with dexamethasone for newly diagnosed or relapsed/refractory cases. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Used for patients whose disease has relapsed or progressed after at least two prior therapies, one of which included bortezomib. Follicular Lymphoma (FL): Administered in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lenome 5 mg Works Direct Cytotoxicity: It binds to the Cereblon (CRBN) protein, part of the E3 ubiquitin ligase complex. This leads to the selective degradation of essential transcription factors (Ikaros and Aiolos) that malignant B-cells and plasma cells rely on for survival. Anti-Angiogenesis: It inhibits the formation of new blood vessels (angiogenesis) by reducing levels of vascular endothelial growth factor (VEGF), essentially “starving“ the tumor of nutrients. Immune Modulation: It stimulates the proliferation and activation of T-cells and Natural Killer (NK) cells, boosting the immune system's ability to identify and destroy cancerous cells. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines like TNF-α and IL-6, which contribute to the survival and spread of cancer cells in the bone marrow microenvironment. Dosage and Administration Guidelines Administration: Lenome 5 mg should be taken orally, once daily, at approximately the same time each day. Method: Swallow the capsule whole with a full glass of water. Do not open, crush, or chew the capsules, as this can affect drug absorption and safety. Timing: It can be taken with or without food. Cycle-Based Therapy: In many protocols, it is taken on a 21-day or 28-day cycle. Always follow the specific dosing schedule prescribed by your oncologist. Safety Profile and Clinical Monitoring Due to its potent biological activity, Lenome 5 mg requires careful medical supervision: Hematological Monitoring: Regular Complete Blood Counts (CBC) are required to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Risk: Lenalidomide increases the risk of blood clots (DVT/PE). Prophylactic anticoagulation (e.g., Aspirin) is often prescribed concurrently. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. It is strictly contraindicated in pregnancy, and both male and female patients must adhere to rigorous pregnancy prevention programs. Common Side Effects: These may include fatigue, diarrhea, muscle cramps, skin rashes, and nausea. Storage and Global Handling Instructions Temperature: Store at room temperature (20°C to 25°C). Original Packaging: Keep capsules in the original bottle or blister pack to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the medication. Keep out of reach of children and pets. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutib 12.5mg Capsule (Sunitinib): Advanced Multi-Kinase Inhibitor for Targeted Oncology Care Sutib 12.5 mg Capsule is a high-potency oral therapeutic agent containing the active substance Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutib is a cornerstone in modern targeted cancer therapy. Manufactured by Cadila Pharmaceuticals (Zydus), it is designed to interfere with the growth and spread of cancer cells by blocking specific signaling pathways that promote tumor angiogenesis (blood vessel formation) and cellular proliferation. Therapeutic Indications and Clinical Usage Sutib 12.5mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often as a first-line therapy to improve progression-free survival. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Indicated for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy) in high-risk patients. Mechanism of Action: How Sutib 12.5mg Works Sutib works through a dual-mechanism approach to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutib 12.5 mg is an oral medication. Capsules should be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (37.5 mg or as adjusted) without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food but should be taken at a consistent time each day to maintain steady-state levels. Safety Profile and Clinical Monitoring Treatment with Sutib 12.5 mg requires vigilant medical oversight for: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Heart Health: Periodic blood tests to check liver enzymes and heart function (LVEF) are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or hair depigmentation during the treatment cycle. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutib 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Malignancies Sutib 12.5 mg Capsule is a high-efficacy oral antineoplastic agent featuring the active pharmaceutical ingredient Sunitinib Malate. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutib is a cornerstone in modern precision oncology. Manufactured by Cadila Pharmaceuticals (Zydus), it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 28-capsule pack is the standard clinical format, meticulously dosed to facilitate the complex “on-off“ cycles required for effective tumor suppression. Therapeutic Indications and Global Clinical Usage Sutib 12.5mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sutib 12.5mg Works Sutib employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Standard Pack Size: 28 Capsules per Bottle/Box. Administration: Sutib 12.5mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (37.5mg or adjusted) without a rest period. Flexibility: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with Sutib 12.5 mg requires consistent medical oversight to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing or hair depigmentation during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutykine 12.5mg Capsule (Sunitinib): Advanced Multi-Kinase Inhibitor for Targeted Oncology Care Sutykine 12.5 mg Capsule is a high-potency oral therapeutic agent containing the active substance Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutykine is a cornerstone in modern targeted cancer therapy. Manufactured by Zuventus Healthcare, it is designed to interfere with the growth and spread of cancer cells by blocking specific signaling pathways that promote tumor angiogenesis (blood vessel formation) and cellular proliferation. Therapeutic Indications and Clinical Usage Sutykine 12.5mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often as a first-line therapy. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Indicated for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy). Mechanism of Action: How Sutykine 12.5mg Works Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutykine helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutykine 12.5 mg is an oral medication. Capsules should be swallowed whole with water. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off. Continuous Regimen (pNET): Often prescribed as a continuous daily dose without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration (e.g., 25 mg, 37.5 mg, or 50 mg) based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food but should be taken at a consistent time each day. Safety Profile and Clinical Monitoring Treatment with Sutykine 12.5 mg requires vigilant medical oversight for: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Pancreatic Health: Periodic blood tests to check liver enzymes and lipase levels are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or “hand-foot syndrome,“ which should be managed by the oncology team. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Svitinib 12.5mg Capsule (Sunitinib): Advanced Multi-Kinase Inhibitor for Targeted Cancer Therapy Svitinib 12.5mg Capsule is a potent, oral multi-kinase inhibitor featuring the active pharmaceutical ingredient Sunitinib. It belongs to a sophisticated class of medications known as tyrosine kinase inhibitors (TKIs). Manufactured by Sun Pharma, a global leader in high-quality pharmaceuticals, Svitinib is engineered to interfere with the growth and spread of cancer cells by blocking specific enzymes that promote tumor vascularization and cellular proliferation. Therapeutic Indications and Clinical Usage Svitinib 12.5mg is a cornerstone in international oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Used as a first-line treatment for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In certain regions, it is utilized as an adjuvant treatment for adult patients at high risk of recurrent RCC following nephrectomy. Mechanism of Action: How Svitinib 12.5mg Works Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By doing so, it “starves“ the tumor by preventing the formation of new blood vessels. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid division of malignant cells. Metastasis Inhibition: By disrupting these signaling pathways, Svitinib helps reduce the ability of the cancer to invade surrounding tissues or spread to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical schedule involves a “4 weeks on, 2 weeks off“ cycle. The dose may be adjusted based on clinical response and tolerability. Continuous Regimen (pNET): For pancreatic neuroendocrine tumors, a continuous daily dose (without a rest period) is often prescribed. Method of Intake: Capsules should be swallowed whole with water. They can be taken with or without food. Consistency: It is recommended to take the medication at the same time each day to maintain stable plasma concentrations. Safety Profile and Professional Monitoring Treatment with Svitinib 12.5mg requires consistent medical oversight to manage potential adverse effects: Hypertension Monitoring: Blood pressure should be monitored regularly, as Sunitinib can cause significant increases. Hematological Checks: Regular Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect. Skin and Hair Changes: Patients may notice skin discoloration (yellowing) or hair depigmentation during the treatment cycles. Liver and Heart Health: Periodic monitoring of liver enzymes and LVEF (heart function) is essential. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or trained caregivers. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Celomide 5mg Capsule (Lenalidomide): Precision Maintenance Therapy for Hematological Oncology. Celomide 5 mg Capsule is a specialized, low-dose immunomodulatory medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), the 5 mg strength is a critical dosage form used primarily for maintenance therapy, dose tapering, and patients requiring renal dose adjustments. Manufactured by Celon Laboratories Pvt. Ltd., Celomide 5mg is an essential component in the long-term management of hematological malignancies, providing a balance between therapeutic efficacy and manageable toxicity. Therapeutic Indications and Clinical Usage Celomide 5 mg is extensively utilized across international oncology protocols for: Multiple Myeloma (MM) Maintenance: Following an autologous stem cell transplant (ASCT) or induction therapy, the 5 mg dose is often used as a long-term maintenance strategy to prevent disease relapse. Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Renal Dose Adjustments: For patients with moderate to severe renal impairment, the 5 mg capsule allows for precise dosing to maintain efficacy while reducing the risk of systemic toxicity. Relapsed/Refractory Lymphoma: Used in combination with other agents for patients with Mantle Cell Lymphoma (MCL) or Follicular Lymphoma who require a lower starting dose or a dose reduction. Mechanism of Action: How Celomide 5mg Works Cereblon Binding: It binds to the protein Cereblon, part of the E3 ubiquitin ligase complex, leading to the selective degradation of transcription factors (Ikaros and Aiolos) necessary for cancer cell survival. Anti-Angiogenesis: It blocks the secretion of pro-angiogenic factors (like VEGF), preventing the tumor from forming the new blood vessels it needs to grow. Immune Surveillance: It enhances the activity of T-cells and Natural Killer (NK) cells, boosting the body’s innate ability to find and destroy residual cancer cells. Cytokine Modulation: It inhibits the production of pro-inflammatory cytokines like TNF-α, which otherwise support the survival of malignant cells in the bone marrow microenvironment. Dosage and Administration Guidelines Maintenance Dosing: In maintenance settings, Celomide 5mg is often taken once daily on a continuous basis or following a “21 days on, 7 days off“ cycle. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Dose Escalation/De-escalation: The 5 mg strength provides oncologists with the flexibility to titrate the dose upward as tolerated or downward to manage hematological toxicities. Safety Profile and Clinical Monitoring Low-dose therapy still requires vigilant professional oversight: Hematological Monitoring: Regular Complete Blood Counts (CBC) are required to monitor for neutropenia and thrombocytopenia, though these are typically less frequent at the 5 mg level than at higher doses. Thromboembolism Prophylaxis: Even at 5 mg, there remains a risk of blood clots (DVT/PE). Anticoagulant therapy (e.g., Aspirin) is frequently continued during maintenance. Embryo-Fetal Toxicity (REMS): Lenalidomide remains a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients regardless of dosage. General Side Effects: Patients may experience mild fatigue, diarrhea, or skin rashes. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep the capsules in the original blister pack to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the medication; if a capsule is broken, wash the area immediately. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Laviat 5 mg Capsule (Lenalidomide): Precision Immunotherapy for Long-Term Oncology Care Laviat 5 mg Capsule is a high-efficacy, low-dose immunomodulatory medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), the 5 mg strength is a vital therapeutic tool used primarily for maintenance therapy, precise dose titration, and treatment regimens for patients with specific renal considerations. Manufactured by Fresenius Kabi Oncology Ltd., Laviat 5mg provides a strategic balance between controlling malignant cell proliferation and maintaining a high quality of life for the patient. Therapeutic Indications and Clinical Usage Laviat 5mg is integrated into global oncology protocols for the management of: Multiple Myeloma (MM) Maintenance: Used as a long-term strategy following autologous stem cell transplant (ASCT) to prolong progression-free survival and prevent disease relapse. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Used for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Often used in combination with Rituximab for adult patients previously treated for follicular or marginal zone lymphoma. Mechanism of Action: How Laviat 5mg Works Cereblon Binding: It binds to the protein Cereblon, a component of the E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors required for cancer cell survival. Immune System Activation: It stimulates T-cells and Natural Killer (NK) cells, significantly increasing the body's natural ability to identify and eliminate tumor cells. Anti-Angiogenesis: It inhibits the development of new blood vessels (angiogenesis) that tumors require for oxygen and nutrient supply. Cytokine Regulation: It suppresses the production of pro-inflammatory cytokines such as TNF-$alpha$ and IL-6, which are known to promote the growth of myeloma cells in the bone marrow microenvironment. Dosage and Administration GuidelinesMaintenance Regimen: The 5 mg dose is frequently taken once daily, often on a cycle of “21 days on, 7 days off“ or as a continuous daily dose depending on the protocol. Administration: Capsules must be swallowed whole with water. Do not open, crush, or chew them. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma levels. Dose Flexibility: The 5 mg strength allows oncologists to de-escalate dosage from 25 mg or 15 mg strengths to manage hematological toxicities effectively. Safety Profile and Clinical Monitoring Medical supervision is mandatory while taking Laviat 5mg: Hematological Vigilance: Regular Complete Blood Counts (CBC) are necessary to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Prophylaxis: There is an increased risk of blood clots (DVT/PE). Most patients are prescribed concurrent anticoagulants (blood thinners). Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients regardless of the dose. Common Side Effects: Fatigue, diarrhea, muscle cramps, and skin rashes are frequently reported and managed with supportive care. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the medication; if a capsule is broken, wash the area immediately with soap and water. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383